Bristol Myers CFO sells 30,000 shares under plan

Bristol Myers Squibb EVP and CFO David V. Elkins reported open-market sales of company stock.

Rhea-AI Filing Summary

Bristol Myers Squibb EVP and CFO David V. Elkins reported open-market sales of company stock. On April 1, 2026, he sold 25,519 shares of common stock at a weighted average price of $61.60 per share and 4,481 shares at $62.05 per share, totaling 30,000 shares. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan. After the sales, he directly held 159,248 shares of Bristol Myers Squibb common stock and had an additional 294.42 shares held indirectly through the BMS Savings and Investment Program, based on a recent 401(k) plan statement.

Insider Trade Summary

Net Seller: 30,000 shares

Net Sell 3 txns

Insider Elkins David V

Role EVP, Chief Financial Officer

Sold 30,000 shs ($1.85M)

Type	Security	Shares	Price	Value
Sale	Common Stock, $0.10 par value	25,519	$61.60	$1.57M
Sale	Common Stock, $0.10 par value	4,481	$62.05	$278K
holding	Common Stock, $0.10 par value	--	--	--

Holdings After Transaction: Common Stock, $0.10 par value — 159,248 shares (Direct); Common Stock, $0.10 par value — 294.42 shares (Indirect, BMS Savings and Investment Program)

Footnotes (4)

1. F1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 3, 2025.
2. F2. The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $60.900 to $61.895, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
3. F3. The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $61.910 to $62.201, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
4. F4. Based on recent 401(k) plan statement.

Key Figures

Shares sold at $61.60: 25,519 shares at $61.60 Shares sold at $62.05: 4,481 shares at $62.05 Total shares sold: 30,000 shares +4 more

7 metrics

Shares sold at $61.60 25,519 shares at $61.60 Open-market sale on April 1, 2026

Shares sold at $62.05 4,481 shares at $62.05 Open-market sale on April 1, 2026

Total shares sold 30,000 shares Aggregate open-market sales reported in Form 4

Direct holdings after sale 159,248 shares Direct common stock held by CFO after transactions

Indirect 401(k) holdings 294.42 shares BMS Savings and Investment Program based on recent 401(k) statement

Weighted price range block 1 $60.900–$61.895 Price range for first group of sales

Weighted price range block 2 $61.910–$62.201 Price range for second group of sales

Key Terms

Rule 10b5-1 trading plan, weighted average sales price, BMS Savings and Investment Program

3 terms

Rule 10b5-1 trading plan regulatory

"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sales price financial

"The price reported reflects the weighted average sales price. The shares were sold in multiple transactions"

BMS Savings and Investment Program financial

"Based on recent 401(k) plan statement."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Bristol Myers Squibb (BMY) disclose for its CFO?

Bristol Myers Squibb disclosed that EVP and CFO David V. Elkins sold 30,000 shares of common stock in open-market transactions. The sales occurred on April 1, 2026, and were executed under a pre-arranged Rule 10b5-1 trading plan.

At what prices did the Bristol Myers Squibb (BMY) CFO sell his shares?

The Bristol Myers Squibb CFO sold 25,519 shares at a weighted average price of $61.60 and 4,481 shares at a weighted average price of $62.05. Both transactions were reported as open-market sales on April 1, 2026.

How many Bristol Myers Squibb (BMY) shares does the CFO hold after the Form 4 sales?

After the reported sales, the CFO held 159,248 Bristol Myers Squibb common shares directly. He also had 294.42 additional shares held indirectly through the BMS Savings and Investment Program, based on a recent 401(k) plan statement.

Were the Bristol Myers Squibb (BMY) CFO share sales made under a Rule 10b5-1 plan?

Yes. The filing states the CFO’s share sales were effected pursuant to a Rule 10b5-1 trading plan adopted on June 3, 2025. Such plans pre-schedule trades, indicating these transactions were planned in advance rather than timed discretionarily.

What does weighted average sales price mean in the BMY CFO Form 4?

The weighted average sales price reflects multiple trades executed within a price range on the transaction date. For these Bristol Myers Squibb sales, prices ranged from $60.900 to $61.895 for one block and $61.910 to $62.201 for the other, averaged for reporting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/02/2026 - 04:29 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Elkins David V

(Last) (First) (Middle)

BRISTOL-MYERS SQUIBB COMPANY

ROUTE 206 AND PROVINCE LINE ROAD

(Street)

PRINCETON NEW JERSEY 08543

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BRISTOL MYERS SQUIBB CO [ BMY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, $0.10 par value	04/01/2026		S		25,519(1)	D	$61.6(2)	163,729	D
Common Stock, $0.10 par value	04/01/2026		S		4,481(1)	D	$62.05(3)	159,248	D
Common Stock, $0.10 par value								294.42(4)	I	BMS Savings and Investment Program

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 3, 2025.

2. The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $60.900 to $61.895, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.

3. The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $61.910 to $62.201, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.

4. Based on recent 401(k) plan statement.

Remarks:

	/s/ Amy Fallone, attorney-in-fact for David V. Elkins	04/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)